Kevin Harrington: STING Agonist Therapy with Ulevostinag – From ESMO 2018 to Print
Kevin Harrington, Professor in Biological Cancer Therapies at Institute of Cancer Research, shared a post on LinkedIn:
“Delighted to announce the publication of this paper in Clinical Cancer Research. The paper reports on two trials of intratumoural cyclic dinucleotide STING agonist therapy with Ulevostinag (MK1454) in patients with a variety of solid cancers and lymphoma. The preliminary data were first presented at ESMO in 2018; so, it has been a long road to get it into print.
Although this paper deals largely with treatment-related toxicity and the pharmacokinetic and pharmacodynamic effects of MK1454, it is important to recognise that there are still surviving patients who entered these protocols up to 7 years ago. We hope to report on the outcome data in a follow-on paper led by the co-authors of this study.
Especial thanks go to friends and colleagues at Merck who persevered in getting the data assembled, cleaned and analysed and to all of the study teams who brought this treatment opportunity to patients under their care. Above all, grateful thanks to the patients who agreed to receive this treatment and to their families and carers who supported them through the trial.”
Title: Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas
Authors: Kevin J Harrington, Stephane Champiat, Joshua D Brody, Byoung Chul Cho, Emanuela Romano, Talia Golan, John R Hyngstrom, James Strauss, David Y Oh, Aron Popovtzer, Carlos Gomez-Roca, Ruth Perets, Sung-Bae Kim, Deborah J Wong, Steven F Powell, Anuradha Khilnani, Thomas Jemielita, Qing Zhao, Runchen Zhao, Matthew Ingham
More posts featuring Cancer Research on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023